Gilead Sciences (GILD) Tops Q4 EPS by 1c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities
February 11, 2026 8:36 AM ESTBofA Securities analyst Tim Anderson raised the price target on Gilead Sciences (NASDAQ: GILD) to $162.00 (from $154.00) while maintaining a Buy rating.
The analyst comments "GILD reported strong 4Q product revenues of $7.9bn ahead of Street estimates (BofA: +4%, cons: +4%) driven by demand outperformance from... More



